Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients

Frontiers in Medicine

Medicine

Liming Wu¹  Kamran Ali²  Tianci Xie²  Kai Gao²  Jinpeng Shan²  Min Chen²  YunMi Qiu²  Yiling Yu² 

[1] Department of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China;Department of Dermatology, The Fourth School of Medicine Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China;

关键词: Staphylococcus aureus;    adverse event;    atopic dermatitis;    dupilumab adverse reactions;    drug reaction;   

DOI  :  10.3389/fmed.2023.1027589

 received in 2022-08-25, accepted in 2023-02-16,  发布年份 2023

来源: Frontiers

【 摘 要 】

Dupilumab was the first biological medication licensed to treat atopic dermatitis (AD), and it has shown remarkable effectiveness and safety in the treatment of moderate-to-severe atopic dermatitis. There are limited drug-related adverse events associated with dupilumab in atopic dermatitis (AD) treatment. Here, we present two cases of local Staphylococcus aureus infection during the treatment of atopic dermatitis with dupilumab.

【 授权许可】

Unknown   
Copyright © 2023 Chen, Gao, Ali, Shan, Qiu, Xie, Yu and Wu.